{"title":"细胞选择性靶向嵌合体(SelecTACB)在B细胞上降解膜蛋白","authors":"Zhenlin Yang, , , Jianfei Jiang, , , Yuhui Cao, , , Haoming Fang, , , Xianrui Zhang, , , Yuxuan Zhang, , , Heng Zhang*, , and , Peng R. Chen*, ","doi":"10.1021/jacs.5c09630","DOIUrl":null,"url":null,"abstract":"<p >Membrane protein degradation chimeras (MPDs) have expanded the application space of current targeted protein degradation technologies (TPDs), yet cell-selective MPDs are still lacking, particularly for surface proteins on immune cells. Precise degradation of a target protein on a specific cell type is challenging when it is expressed across multiple immune cell types. Here, we introduce SelecTAC<sup>B</sup> as a targeted membrane protein degradation chimera that is selective on B cells. By leveraging CD22 as the B cell specific lysosome-targeting receptor to induce endocytosis and lysosome degradation, SelecTAC<sup>B</sup> allowed membrane protein degradation in a targeted and cell-selective manner. We show that SelecTAC<sup>B</sup> can effectively degrade indicated proteins such as CD40 and ICOSL on B cells from human peripheral blood mononuclear cells (PBMCs) without affecting protein expression in other immune cell types. The degradation of key proteins involved in T cell stimulation pathways led to sustained inhibition of B cell functions. Together, our work established a cell-type selective degradation platform that offers a general strategy for targeted membrane protein degradation on immune cells.</p>","PeriodicalId":49,"journal":{"name":"Journal of the American Chemical Society","volume":"147 40","pages":"36301–36309"},"PeriodicalIF":15.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cell-Selective Targeting Chimeras (SelecTACB) for Membrane Protein Degradation on B Cells\",\"authors\":\"Zhenlin Yang, , , Jianfei Jiang, , , Yuhui Cao, , , Haoming Fang, , , Xianrui Zhang, , , Yuxuan Zhang, , , Heng Zhang*, , and , Peng R. Chen*, \",\"doi\":\"10.1021/jacs.5c09630\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Membrane protein degradation chimeras (MPDs) have expanded the application space of current targeted protein degradation technologies (TPDs), yet cell-selective MPDs are still lacking, particularly for surface proteins on immune cells. Precise degradation of a target protein on a specific cell type is challenging when it is expressed across multiple immune cell types. Here, we introduce SelecTAC<sup>B</sup> as a targeted membrane protein degradation chimera that is selective on B cells. By leveraging CD22 as the B cell specific lysosome-targeting receptor to induce endocytosis and lysosome degradation, SelecTAC<sup>B</sup> allowed membrane protein degradation in a targeted and cell-selective manner. We show that SelecTAC<sup>B</sup> can effectively degrade indicated proteins such as CD40 and ICOSL on B cells from human peripheral blood mononuclear cells (PBMCs) without affecting protein expression in other immune cell types. The degradation of key proteins involved in T cell stimulation pathways led to sustained inhibition of B cell functions. Together, our work established a cell-type selective degradation platform that offers a general strategy for targeted membrane protein degradation on immune cells.</p>\",\"PeriodicalId\":49,\"journal\":{\"name\":\"Journal of the American Chemical Society\",\"volume\":\"147 40\",\"pages\":\"36301–36309\"},\"PeriodicalIF\":15.6000,\"publicationDate\":\"2025-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American Chemical Society\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/jacs.5c09630\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American Chemical Society","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/jacs.5c09630","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Cell-Selective Targeting Chimeras (SelecTACB) for Membrane Protein Degradation on B Cells
Membrane protein degradation chimeras (MPDs) have expanded the application space of current targeted protein degradation technologies (TPDs), yet cell-selective MPDs are still lacking, particularly for surface proteins on immune cells. Precise degradation of a target protein on a specific cell type is challenging when it is expressed across multiple immune cell types. Here, we introduce SelecTACB as a targeted membrane protein degradation chimera that is selective on B cells. By leveraging CD22 as the B cell specific lysosome-targeting receptor to induce endocytosis and lysosome degradation, SelecTACB allowed membrane protein degradation in a targeted and cell-selective manner. We show that SelecTACB can effectively degrade indicated proteins such as CD40 and ICOSL on B cells from human peripheral blood mononuclear cells (PBMCs) without affecting protein expression in other immune cell types. The degradation of key proteins involved in T cell stimulation pathways led to sustained inhibition of B cell functions. Together, our work established a cell-type selective degradation platform that offers a general strategy for targeted membrane protein degradation on immune cells.
期刊介绍:
The flagship journal of the American Chemical Society, known as the Journal of the American Chemical Society (JACS), has been a prestigious publication since its establishment in 1879. It holds a preeminent position in the field of chemistry and related interdisciplinary sciences. JACS is committed to disseminating cutting-edge research papers, covering a wide range of topics, and encompasses approximately 19,000 pages of Articles, Communications, and Perspectives annually. With a weekly publication frequency, JACS plays a vital role in advancing the field of chemistry by providing essential research.